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Purpose: There is an urgent need to develop effective therapies and treatment strategies to treat 
hypoxic tumors, which have a very poor prognosis and do not respond well to existing therapies.
Methods: A novel hypoxia-targeting agent, KEMTUB012-NI2, was synthesized by conjugating 
a 2-nitroimidazole hypoxia-targeting moiety to a synthetic tubulysin, a very potent antimitotic. 
Its hypoxic selectivity and mode of action were studied in breast cancer cell lines.
Results: KEMTUB012-NI2 exhibited a similar selectivity for hypoxic cells to that of tira-
pazamine, a well-established hypoxia-targeting agent, but was >1,000 times more potent in cell 
cytotoxicity assays. The hypoxia-targeting mechanism for both KEMTUB012-NI2 and tirapaza-
mine was selective and mediated by one-electron reductases. However, while cytochrome p450 
reductase (POR) downregulation could inhibit tirapazamine cytotoxicity, it actually sensitized 
hypoxic cells to KEMTUB012-NI2.
Conclusion: KEMTUB012-NI2 is a potent new agent that can selectively target hypoxic cancer 
cells. The hypoxia selectivity of KEMTUB012-NI2 and tirapazamine appears to be differen-
tially activated by reductases. Since reductases are heterogeneously expressed in tumors, the 
different activation mechanisms will allow these agents to complement each other. Combining 
POR downregulation with KEMTUB012-NI2 treatment could be a new treatment strategy that 
maximizes efficacy toward hypoxic tumor cells while limiting systemic toxicity.
Keywords: breast cancer, tubulysin, anti-mitotic, hypoxia, cell death, reductase
Introduction
Cells that are exposed to hypoxic (low oxygen) conditions are characteristic of locally 
advanced solid tumors and have been described in a wide range of human malignan-
cies.1 Up to 50%–60% of locally advanced solid tumors exhibit regions of hypoxic 
and/or anoxic tissue that are heterogeneously distributed within the tumor mass. 
Tumors with high hypoxic volumes have a poor prognosis and an aggressive tumor 
phenotype and exhibit increased risk of invasion and metastasis.2,3 It is also well 
established that hypoxic cells respond poorly to radiotherapy and chemotherapy. The 
decreased effectiveness of radiotherapy at low oxygen concentrations is primarily a 
result of reduced free radical formation.1,4 The efficacy of standard chemotherapies in 
hypoxic tumors is affected by multiple factors as follows: 1) poor tumor vasculature 
can limit drug delivery to hypoxic cells; 2) the low pH of the extracellular environment 
can alter the ionic charge of the drug; 3) limited cell proliferation can significantly 
reduce the efficacy of agents that target cycling cells; 4) hypoxic cells have decreased 
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susceptibility to apoptosis; and 5) hypoxic cells frequently 
upregulate multidrug-resistant transporters.1,4,5 Accordingly, 
specific agents have been developed to overcome these issues 
and provide new therapeutic strategies that have the potential 
to selectively target hypoxic cells.
Researchers have explored the following two main strate-
gies to develop therapeutics that selectively target hypoxic 
cells:6 targeting the hypoxia inducible factor 1 (HIF1) 
pathway, the master regulator of the hypoxia response, and 
designing bioreductive prodrugs that become activated in 
hypoxic cells. The former approach has had limited success 
to date, as the prospective molecules either are not specific 
for hypoxic cells or produce pleiotropic effects.6 The latter 
approach has yielded the following four classes of bioreduc-
tive compounds:7,8 nitroaromatics (eg, 2-nitroimidazole-
containing compounds such as nimorazole and PR104A), 
aromatic N-oxides (eg, tirapazamine), aliphatic N-oxides 
(eg, banoxantrone), and quinones (eg, apaziquone). With the 
exception of nimorazole that is used in Denmark to treat some 
hypoxic tumors, none of these bioreductive agents have been 
approved for clinical use, due to limited efficacy in clinical 
trials. This is partly because of a lack of reliable methods to 
stratify patients into hypoxic and nonhypoxic groups prior 
to therapy4 and also reflects the limitations of the current 
bioreductive agents. Tirapazamine, widely considered as 
the leading aromatic N-oxide, is only active at micromolar 
concentrations in cells,9 making it challenging to deliver an 
efficacious drug dose to hypoxic tumor cells. A modified 
version of tirapazamine (SN30000) has subsequently been 
developed to overcome the issue of poor tumor penetration.10 
Another leading candidate, banoxantrone, displays very lim-
ited selectivity for hypoxic cells in vitro.11 Achieving efficacy 
with bioreductive agents in clinical trials is, therefore, likely 
to require development of more effective agents, utilizing 
improved treatment strategies and only using these therapies 
in hypoxic tumors.
Tubulysins are natural tetrapeptides that inhibit tubulin 
polymerization by binding to tubulin near the vinca alkaloid 
binding site. Synthetic tubulysin analogs have been synthe-
sized to facilitate their development as anticancer compounds 
because the natural peptides produced by myxobacteria are 
only made in minute quantities. Tubulysins are extremely 
potent inhibitors of mammalian cancer cell proliferation in 
vitro,12,13 block cells in the G
2
/M phase of the cell cycle,12,14,15 
and induce cell death via a mechanism of action that is distinct 
from taxanes.12 However, preclinical experiments indicate 
that they have a narrow therapeutic window,16 and hence may 
be too toxic for use as traditional single agent therapeutics. 
A more favorable strategy could be to use them as targeted 
therapeutics, allowing them to be selectively directed to 
tumor cells and minimizing systemic toxicity. Indeed, this 
approach has been substantiated by conjugating tubulysin to 
trastuzamab;17 the conjugated tubulysin was able to selec-
tively target HER2-expressing cancer cells and xenografts.
In this study, we conjugated synthetic tubulysin analogs to 
2-nitroimidazole to produce new hypoxia-targeted bioreduc-
tive agents. A novel derivative belonging to the synthesized 
compounds, namely KEMTUB012-NI2, exhibited a similar 
selectivity for hypoxic cells to that of tirapazamine, but was 
>1,000 times more potent in cell cytotoxicity assays. More-
over, it was possible to pharmacologically inhibit the hypoxia 
selectivity of the tubulysin analog, demonstrating that the 
hypoxia-targeting mechanism is selective and mediated by 
a one-electron flavoenzyme reductase(s). Finally, down-
regulation of cytochrome p450 reductase (POR) sensitized 
hypoxic cells to the tubulysin analog. These data demonstrate 
that this reductase is not required in the hypoxia-targeting 
mechanism and suggest that combining POR downregula-
tion with tubulysin treatment could form the basis of a novel 
hypoxia-targeting therapy that could maximize efficacy 
toward hypoxic tumor cells while limiting systemic toxicity 
to cancer patients. 
This article does not contain any studies with human 
participants or animals performed by any of the authors.
Methods
Chemistry
Tubulysin analogs KEMTUB001, KEMTUB010, and KEM-
TUB012 (Figure 1) were synthesized according to the previ-
ously reported procedure.18 KEMTUB001 and KEMTUB012 
were coupled via the terminal carboxylic group to compounds 
bearing a 2-nitroimidazole group (NI1, NI2, and NI3) to 
obtain tubulysin derivatives shown in Figure 1. In particular, 
both the tubulysin derivatives were conjugated to 2-(2-nitro-
1H-imidazol-1-yl)ethanamine, NI1.19 KEMTUB012 was 
also coupled to compounds NI2 and NI3, respectively, 
N-(3-aminopropyl)-2-(2-nitro-1H-imidazol-1-yl)acetamide, 
and N-(6-aminohexyl)-2-(2-nitro-1H-imidazol-1-yl)acet-
amide. Assembling of the final tubulysin-based conjugates 
KEMTUB001-NI1, KEMTUB012-NI1, KEMTUB012-NI2, 
and KEMTUB012-NI3 was performed by using conventional 
peptide synthesis in solution procedures (Figure S1). The 
synthetic procedures as well as data concerning the char-
acterization of the synthesized tubulysin analogs and their 
derivatives bearing NI1, NI2, and NI3 groups are reported 
in the Supplementary materials.
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Cell lines, cell culture, and reagents
Experiments were performed in MCF7, MDAMB231 
(MDA231), and MDAMB468 (MDA468) breast cancer cells. 
MCF7 represents the luminal subtype, which characteristically 
expresses estrogen and progesterone receptors.20 MDA231 and 
MDA468 represent the basal-like subtype, which typically 
do not contain estrogen, progesterone, or HER2 receptors 
and generally have a poorer prognosis than luminal tumors.
MCF7, MDA231, and MDA468 cells were purchased from 
American Type Culture Collection and confirmed as authen-
tic and contamination-free. Cell cultures were maintained in 
Roswell Park Memorial Institute (RPMI) containing 10% (v/v) 
fetal calf serum, 100 Units/mL penicillin, and 100 mg/mL 
streptomycin and grown at 37°C in a humidified atmosphere 
containing 5% CO
2
. All reagents were purchased from Sigma-
Aldrich (St Louis, MO, USA), unless stated otherwise.
3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) 
cell cytotoxicity assays
For standard cytotoxicity experiments, cells were seeded in 
96-well plates at 5,000 cells/well, then left to settle overnight. 
Stock solutions of test compounds (KemoTech Srl, Pula (CA), 
Italy, www.kemotech.it) were prepared in dimethyl sulfoxide 
(DMSO). Cells were treated with a range of drug concentra-
tions for 24 h in triplicate wells in normoxic (21% O
2
) or 
hypoxic conditions (1% O
2
). Medium was then aspirated and 
replaced with fresh RPMI. Cells were left to grow for 48 h 
Figure 1 Chemical structures of tubulysin analogs. (A) Structures of nitroimidazole-tubulysin conjugates. (B) Structures of tubulysins.
 
H
yp
ox
ia
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
27
 o
n 
25
-M
ay
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Hypoxia 2017:5submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
48
Lazzari et al
in normoxic conditions and the number of viable cells in 
each well estimated by incubating cells in media containing 
0.5 mg/mL MTT cell proliferation reagent for 1–2 h. Medium 
was aspirated, the formazan product solubilized in DMSO21 
and measured at 540 nM in a microplate reader. GraphPad 
Prism was used to calculate IC
50
 values.
Western blot analysis
MCF7 and MDA231 cells were seeded at 0.35×106/60 mm 
plates and left to settle overnight. Cells were incubated with 
DMSO or KEMTUB012-NI2 at the specified concentration for 
the time indicated. The protein concentration in the resulting 
lysates was determined by bicinchoninic acid assay. Blotting 
was done essentially as described previously.22 Membranes 
were probed with the following antibodies: cleaved PARP 
(cell signaling), POR (Santa Cruz Biotechnology, Dallas, 
TX, USA), methionine synthase reductase (MTRR; Abcam, 
Cambridge, UK), diflavin oxidoreductase-1 (NDOR1), and 
β-actin (both Sigma-Aldrich). After 4×5 min washes in phos-
phate buffered saline containing 0.1% Tween20, membranes 
were incubated for 1 h with the appropriate infrared dye-
conjugated secondary antibody (Licor, Lincoln, NE, USA) 
diluted 1:10,000. Images were captured with an Odyssey® 
CLx LI-CORE imaging system and densitometries of target 
proteins measured using Image studio Lite.
POR small interfering RNA (siRNA) cell 
transfection experiments
MCF7 and MDA231 cells were seeded in 96-well plates at 
2,000 cells/well or in 60 mm plates at 0.2×106/60 mm plate 
and left to settle overnight. Next day, the cells were trans-
fected with a random siRNA or POR siRNA (both Santa 
Cruz Biotechnology) using Jetprime transfection reagent 
(Source Bioscience, Nottingham, UK), using the protocol 
recommended by the manufacturer. Medium was changed the 
next day to remove transfection reagent. Cells were grown 
for another 24 h to maximize POR downregulation before 
any additional treatments were initiated.
Trypan blue exclusion assay to detect 
dead cells
Cells were seeded as described for Western blot experi-
ments, then treated with the indicated concentrations of 
KEMTUB012-NI2 for the time shown. In some experiments, 
POR was downregulated by siRNA treatment prior to addi-
tion of KEMTUB012-NI2. Adherent cells in each plate were 
trypsinized and combined with floating cells collected by 
centrifugation (1,000 g × 4 min) from the culture medium. 
Cells were incubated with trypan blue for 5 min, then the 
proportion of blue (dead) and transparent (live) cells counted 
in a hemocytometer.12,23
Results
Synthetic tubulysins such as KEMTUB010 are very potent 
anticancer agents in normoxic breast cancer cells, with 
picomolar concentrations inhibiting cell proliferation and 
inducing cell death.12 Experiments in MCF7 and MDA231 
cells indicated that KEMTUB010 was similarly cytotoxic 
in hypoxic and normoxic conditions (Table 1). Indeed, in 
MCF7 cells chronic hypoxia significantly decreased the 
KEMTUB010 IC
50
 value, producing a normoxia:hypoxia 
(N:H) selectivity ratio >1, indicating enhanced cytotoxicity 
in hypoxic cells. This is likely a cell line-dependent effect 
since an equivalent decrease was not detected in MDA231 
cells. In contrast, the well-established bioreductive anticancer 
agent tirapazamine was more effective in chronic hypoxia in 
Table 1 Effect of hypoxia treatment on cell cytotoxicity of tubulysin analogs
Compound MCF7 MDA231 MDA468
Normoxia 
(IC50, nM)
Hypoxia  
(IC50, nM)
N:H Normoxia  
(IC50, nM)
Hypoxia  
(IC50, nM)
N:H Normoxia  
(IC50, nM)
Hypoxia  
(IC50, nM)
N:H
KEMTUB010 0.0368±0.0038 0.0131±0.0023 2.8 0.059±0.0056 0.0587±0.0064 1.0
KEMTUB012 0.016±0.0076 0.010±0.0052 1.6 0.0355±0.0122 0.0259±0.012 1.4 0.0321±0.027 0.0241±0.0006 1.3
KEMTUB001 0.0183±0.0083 0.01.7±0.0018 1.6 0.0412±0.0133 0.0323±0.014 1.3
KEMTUB001-NI1 0.915±0.173 0.586±0.146 1.6 1.450±0.203 1.207±0.374 1.2
KEMTUB012-NI1 0.854±0.336 0.433±0.386 2.0 1.466±0.250 0.943±0.234 1.6
KEMTUB012-NI3 6.335±2.712 1.728±0.744 3.7* 10.937±2.436 4.769±1.772 2.3* 3.012±0.138 2.110±437* 1.4*
KEMTUB012-NI2 3.415±1.092 0.502±0.216 6.8* 6.050±1.946 1.904±0.856 3.2* 1.284±0.594 284±32 4.5*
Tirapazamine 36,900±9,300 3,500±900 10.6** 68,000±10.3 22,200±2,300 3.1** 4,967±2,700 500±200 9.1**
Notes: Cells were treated with a range of drug concentrations in normoxic (21% O2) or hypoxic (1% O2) conditions for 24 h. Medium was then aspirated and replaced with 
fresh RPMI and cells grown for 48 h in normoxic conditions. An MTT cell cytotoxicity assay was then performed. Results are the average ± SD of at least three independent 
experiments performed in triplicate. N:H ratio compares normoxic versus hypoxic IC50 value for each molecule. A compound with an N:H value of >1 is more effective in 
hypoxic conditions. Statistically significant differences between each treatment in hypoxic and normoxic conditions are shown (**P<0.01, *P<0.05).
Abbreviations: MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; N:H, normoxia:hypoxia; RPMI, Roswell Park Memorial Institute; SD, standard deviation.
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both cell lines tested. Acute hypoxia treatments did not have 
any significant effect on tirapazamine or KEMTUB010 IC
50
 
values in either cell line (data not shown). These data indicate 
that synthetic tubulysins are at least as potent under hypoxic 
as normoxic conditions. Therefore, we hypothesized that 
conjugating tubulysin to nitroimidazole, a well-established 
hypoxia-targeting moiety, could create a potent anticancer 
agent that selectively targets hypoxic cells. For this scope, 
novel tubulysin derivatives bearing a 2-nitroimidazole moiety 
(Figure 1) were synthesized starting from synthetic tubulysins 
belonging to the same series of KEMTUB010.12
Cells were treated with each compound in both normoxic 
and hypoxic conditions. The MTT assays were performed in 
normoxic conditions to ensure that the formation of forma-
zan by mitochondria was not influenced by low oxygen 
levels. The nitroimidazole group alone was not cytotoxic at 
the concentrations tested here (IC
50
 value >1 µM, data not 
shown). The tubulysins KEMTUB001 and KEMTUB012 
were exceptionally potent in breast cancer cells, but hypoxic 
conditions had no significant effect on their IC
50
 values (Table 
1). Linking a nitroimidazole group to either of these tubu-
lysins increased the IC
50
 value by 1–2 orders of magnitude, 
indicating that the conjugation of the targeting moiety at the 
terminal carboxylic group of the tubulysin analogs moderately 
reduces the effectiveness of these agents. In cytotoxicity 
assays, KEMTUB001-NI1 generated an N:H ratio similar 
to KEMTUB001 in both MCF7 and MDA231 cells, indi-
cating that the nitroimidazole moiety does not enhance its 
hypoxia selectivity. Likewise, the IC
50
 value of KEMTUB012 
conjugate the KEMTUB012-NI1 was not noticeably influ-
enced by hypoxia. In contrast, the KEMTUB012 conjugates 
KEMTUB012-NI2 and KEMTUB012-NI3 had significantly 
lower IC
50
 values under hypoxic conditions (Table 1), with 
hypoxia treatment shifting the dose curves to the left (eg, Fig-
ure 2A). KEMTUB012-NI2 displayed the highest N:H ratios 
in all cell lines; these were of the same order of magnitude 
as tirapazamine and significantly higher than banoxantrone, 
which displayed no significant selectivity for hypoxic MCF7 
or MDA231 cells (data not shown). The lower IC
50
 values 
observed with KEMTUB012-NI2 and KEMTUB012-NI3 
in hypoxic conditions represent decreased cell growth and/
or increased cell death. KEMTUB012-NI2 was >1,000 times 
more potent than tirapazamine in hypoxic conditions in all 
cell lines tested.
The effect of oxygen concentration on the cytotoxic 
effect of KEMTUB012-NI2 was investigated in MCF7 and 
MDA231 cells (Figure 2B). In both cell lines, the N:H ratio 
increased as the O
2
 concentration decreased from 5% to 
1%. However, the cytotoxic effect was not further enhanced 
by decreasing the O
2
 concentration to 0.1% in either cell 
line. To better understand this trend, we evaluated cellular 
uptake of a radiolabeled nitroimidazole-conjugated mol-
ecule, 18F-fluoroazomycin arabinofuranoside (FAZA). FAZA 
uptake by MCF7 cells increased steadily as O
2
 concentrations 
decreased from 5% to 0.1% (data not shown), confirming 
that cellular uptake of nitroimidazoles is not limited at low 
oxygen levels. Therefore, it seems likely that the absence 
of increased KEMTUB012-NI2 cytotoxicity between 1% 
and 0.1% O
2
 is not due to restricted uptake of the molecule.
Since induction of cell death is an important element of 
the tubulysin mode of action in cancer cells,12 we investigated 
whether the enhanced cytotoxic effect of KEMTUB012-NI2 
in hypoxic cells could involve increased apoptosis or cell 
death. Initial experiments focused on induction of cPARP, a 
well-established biomarker of apoptosis. KEMTUB012-NI2 
treatment caused a definite increase in cPARP generation 
in hypoxic, but not normoxic, MCF7 and MDA231 cells 
(Figure 2C and D). Induction of cPARP was observed with 
2× IC
50
 KEMTUB012-NI2 in both cell lines, and this effect 
was not increased by using a higher KEMTUB012-NI2 dose. 
Trypan blue exclusion experiments were also performed, 
to determine if KEMTUB012-NI2 treatment increases the 
percentage of dead cells in hypoxic conditions. Indeed, 2× 
IC
50
 KEMTUB012-NI2 causes a significant increase in dead 
cells in hypoxic but not normoxic conditions in both cell 
lines (Figure 2E). These data confirm that at least part of 
the enhanced cytotoxic effect observed with KEMTUB012-
NI2 in hypoxic cells is due to enhanced cell death. Higher 
KEMTUB012-NI2 concentrations induced cell death in both 
normoxic and hypoxic conditions.
Reduction of the nitroimidazole group by cellular reduc-
tases is credited with causing retention of nitroimidazole-
conjugated molecules in viable hypoxic cells. However, the 
evidence supporting this model is very limited and the prin-
cipal reductases involved in the process have not been clearly 
identified. Diphenyliodonium chloride (DPI) is an irrevers-
ible inhibitor of flavoenzymes that catalyze one-electron 
reduction reactions.24 The reduced flavoprotein cofactor in 
one-electron reductases can reduce DPI, producing a phenyl 
radical. This can subsequently react with the flavoprotein to 
create a phenylated flavin, which uncompetitively inhibits 
the reductase. Experiments were, therefore, performed in the 
presence and absence of DPI to investigate the role of these 
enzymes in the hypoxia selectivity of KEMTUB012-NI2. 
Inclusion of DPI completely inhibited the hypoxia selectiv-
ity of KEMTUB012-NI2 in cytotoxic assays in both MCF7 
(Figure 3A) and MDA231 cells (Figure 3B). Similar results 
were obtained for tirapazamine, whereas DPI had no effect 
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on the cytotoxicity of banoxantrone (data not shown). DPI 
also completely abrogated the KEMTUB012-NI2-induced 
increase in dead MCF7 (Figure 3C) and MDA231 cells 
(Figure 3D) and the hypoxia-induced increase in cPARP 
(Figure 3E and F). These results clearly demonstrate that the 
hypoxia-selective cytotoxicity of KEMTUB012-NI2 is medi-
ated via a specific process, and a reductase(s) that catalyzes 
one-electron reduction reactions is involved.
It has been reported that the one-electron reductase 
POR is involved in activating SN3000010,25 and PR104A26 
under anoxic conditions, but that other unidentified reduc-
tases also make important contributions.10,25,26 Western blot 
analysis established that POR and several other one-electron 
reductases are expressed in a range of breast cancer cell 
lines (Figure 4A). Novel diflavin oxidoreductase (NDOR1) 
was expressed at similar levels in all cell lines tested. In 
–2
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(D) Quantitation of cPARP data. (E) Trypan blue exclusion assays in MCF7 and MDA231 cells. (B, D, and E) Each data set is the average ± SD of at least three independent 
experiments. Statistically significant comparisons in cPARP quantitation and trypan blue exclusion experiments are shown in graphs (**P<0.01).
Abbreviations: MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; cPARP, cleaved PARP; SD, standard deviation.
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contrast, MTRR expression (upper band – Figure 4B and C) 
was relatively low in MCF7 and BT474 cells, whereas POR 
expression ranged from relatively low in MDA231 cells to 
high in MCF7, BT474, and SkBr3.
A POR-specific siRNA was used to investigate the role 
of this reductase in activation of bioreductases in the cell 
line models used here. POR expression was consistently 
decreased by ~80%–90% after 48 h (Figures 4 and 5A). In 
normoxic conditions, POR downregulation had no significant 
effect on cell cytotoxicity in MCF7 or MDA231 cells in the 
presence or absence of tirapazamine or KEMTUB012-NI2 
(Figure 5B and C). Likewise, under hypoxic conditions POR 
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Figure 3 The hypoxia selectivity of KEMTUB012-NI2 involves reductase(s) that catalyze one-electron reductions.
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siRNA treatment alone did not have a significant effect on cell 
cytotoxicity in either cell line. POR downregulation did, how-
ever, significantly decrease the cytotoxicity of tirapazamine in 
hypoxic MCF7 cells, but enhanced tirapazamine cytotoxicity 
in MDA231 cells (Figure 5B). These results imply that POR 
makes an important contribution to tirapazamine activation 
in MCF7 cells, but not in MDA231 cells, which express low 
POR levels (Figure 4A). In the presence of KEMTUB012-
NI2, POR siRNA treatment caused a significant increase 
in cell cytotoxicity in hypoxic MCF7 and MDA231 cells 
(Figure 5C). POR downregulation also increased the propor-
tion of dead cells (Figure 5D and E) in KEMTUB012-NI2-
treated hypoxic cells. Therefore, since POR downregulation 
sensitizes hypoxic cells to KEMTUB012-NI2, combining 
these treatments could be an effective strategy to maximize 
the hypoxia selectivity of KEMTUB012-NI2.
Discussion
Development of effective treatments for hypoxic tumor 
cells has been a priority ever since it was recognized that 
hypoxic tumors are associated with a poor outcome for cancer 
patients2,3 and are resilient to established radiotherapy and 
chemotherapy treatments. Chemotherapies that specifically 
target hypoxic tumor cells offer an opportunity to selectively 
kill hypoxic cells with limited effect to normoxic cells, 
thereby minimizing systemic toxicity for patients. How-
ever, research activities have not yet translated into routine 
clinical treatments. Several distinct bioreductive agents have 
produced promising results in vitro, yet have disappointed 
in clinical trials.7,8 This is partly a result of not preselecting 
patients with hypoxic tumors for bioreductive agent therapy; 
in two clinical studies where hypoxic tumors were identified 
using Positron Emission Tomography imaging, it was dem-
onstrated that only patients with hypoxic tumors benefited 
from bioreductive drugs.27,28 The limitation of the prevailing 
bioreductases is also a contributing factor. Well-documented 
issues include the limited tumor penetration of tirapazamine10 
and the lack of selectivity of banoxantrone for hypoxic can-
cer cells.11 New hypoxia-selective agents and/or alternative 
treatment strategies are required to advance hypoxia-targeted 
therapies into routine treatments that are consistently effec-
tive in hypoxic tumors.
We report here a novel tubulysin analog, KEMTUB012-
NI2, that selectively targets hypoxic cancer cells. Selectiv-
ity was demonstrated in multiple breast cancer cell lines 
(Table 1) and required the nitroimidazole targeting moiety, 
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as unconjugated tubulysin did not selectively target hypoxic 
cells. In hypoxic cells, KEMTUB012-NI2 induced the char-
acteristic increase in cytotoxicity (Table 1) and cell death 
(Figure 2) previously described for tubulysin analogs.12 Under 
moderate (1% O
2
) hypoxic conditions, KEMTUB012-NI2 
exhibited a similar selectivity for hypoxic cells to that of 
tirapazamine and was superior to banoxantrone. However, 
KEMTUB012-NI2 efficacy was not further increased at lower 
oxygen concentrations (Figure 2B), presumably because any 
potential benefit of improved KEMTUB012-NI2 uptake is 
counterbalanced by the very low cell cycling rate, which will 
limit the effectiveness of the tubulysin. KEMTUB012-NI2 
exhibited an IC
50
 concentration in the low nanomolar range, 
which compares favorably with both tirapazamine and bano-
xantrone, which are both efficacious at micromolar concen-
trations (Table 1).9 A much lower dose of KEMTUB012-NI2 
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will therefore be required to impact hypoxic cells, making it 
less likely to be limited by poor tumor penetration.
Identifying the reductase(s) involved in bioreductase 
activation/tumor uptake is essential to utilize these agents 
to their maximum potential and enable predictions about 
whether an agent is likely to be effective in a particular tumor. 
The data presented here indicate that KEMTUB012-NI2, 
tirapazamine, and banoxantrone are differentially activated 
by reductases. Banoxantrone was not affected by DPI, con-
sistent with the literature that suggests that it utilizes two-
electron reductases such as cytochrome P450 enzymes29 or 
inducible nitric oxide synthase.30 In contrast, the hypoxia 
selectivity of KEMTUB012-NI2 and tirapazamine were 
both abrogated by DPI (Figure 3), implying a role for one-
electron reductases. Tirapazamine appears to be activated by 
multiple reductases; POR is a key activator in MCF7 cells, 
but other reductases also contribute, as POR downregulation 
only partially decreased its cytotoxicity in MCF7 cells and 
did not decrease cytotoxicity in MDA231 cells (Figure 5B). 
These data are broadly consistent with previous studies 
that identified POR as a major determinant of sensitiv-
ity to hypoxia-activated agents, such as SN3000010,25 and 
PR104A.26 Yet other reductases clearly also make important 
contributions, and their relative importance appears to be 
cell line dependent. It is not yet apparent which reductase(s) 
activates KEMTUB012-NI2, since POR downregulation 
actually enhanced the effect of KEMTUB012-NI2 in MCF7 
and MDA231 cells  (Figure 5C). These data indicate that 
POR is not necessary for KEMTUB012-NI2 activation, but 
actually may play an important role in cell survival under 
hypoxic conditions. To our knowledge, this is the first report 
of cytotoxic synergy between a hypoxia-selective agent and 
POR downregulation and could form the basis of a thera-
peutic mechanism to sensitize cells to this agent. The fact 
that a corresponding effect was observed for tirapazamine 
in MDA231 cells (Figure 5B) indicates that this effect is not 
restricted to KEMTUB012-NI2 and may be representative 
of a more general mechanism. An equivalent effect was not 
observed in MCF7 cells (Figure 5B), presumably due to a 
requirement for POR in its activation mechanism.
Combination of POR downregulation with KEMTUB012-
NI2 treatment in hypoxic cells also resulted in a synergistic 
increase in cell death (Figure 5D and E). The fact that this 
effect was only observed in hypoxic conditions using POR 
siRNA treatment but not with random siRNA argues that it is 
not a result of toxicity during the transfection process. Indeed, 
as the effect was only observed under hypoxic conditions, 
it appears as if POR downregulation can sensitize cells to 
the hypoxia-targeted tubulysin, equivalent to a synergistic 
drug combination treatment. POR plays a critical role as the 
principal redox partner for the microsomal p450 enzymes 
responsible for drug and xenobiotic metabolism, cholesterol 
and bile synthesis, and heme breakdown.31 Therefore, there 
are multiple potential mechanisms that could account for 
the observed increase in cytotoxicity and cell death when 
KEMTUB012-NI2 is combined with POR downregulation.
KEMTUB012-NI2 is an exciting prospect for further 
development as a hypoxia-targeting agent. It has compa-
rable selectivity for hypoxic cancer cells as tirapazamine 
under moderate hypoxia, yet is >1,000 times more potent. 
KEMTUB012-NI2 has a distinct mode of action to tira-
pazamine and banoxantrone and is apparently activated by 
different reductases in cells. This could be advantageous as 
POR, a key reductase implicated in tirapazamine activation, 
is apparently only expressed in ~21% of tumors.26 Indeed, 
as downregulation of POR appears to sensitize cells to 
KEMTUB012-NI2, additional experiments are required 
to determine whether downregulation of POR makes cells 
more sensitive to KEMTUB012-NI2 or whether cells that 
naturally express low POR levels are also intrinsically more 
sensitive to KEMTUB012-NI2. Further experiments with 
KEMTUB012-NI2 are warranted to better understand the 
attributes and limitations of this new agent.
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Supplementary materials
Methods
Chemistry
Data concerning the characterization of the synthetic tubu-
lysins KEMTUB001, KEMTUB010, and KEMTUB012, 
and their 2-nitroimidazole derivatives are reported in the 
following sheets.
KEMTUB001: (2S,4R)-4-(2-((1R,3R)-1-acetoxy-
3-((2S,3S)-N-benzyl-3-methyl-2-((R)-1-methylpiper-
idine-2-carboxamido)pentanamido)-4-methylpentyl)
thiazole-4-carboxamido)-2-methyl-5-phenylpentanoic acid
R
f
 = 0.21 (dichloromethane/methanol 95:5). 1H nuclear 
magnetic resonance (NMR) (400 MHz, CD
3
OD) d: 8.07 
(s, 1H), 7.47 (d, J = 7.3 Hz, 2H), 7.39–7.08 (m, 8H), 5.90 
(t, J = 6.8 Hz, 1H), 5.07 (d, J = 17.1 Hz, 1H), 4.74 (d, J = 
8.8 Hz, 1H), 4.46 (d, J = 16.6 Hz, 1H), 4.42–4.29 (m, 2H), 
3.14–3.04 (m, 1H), 3.00–2.82 (m, 3H), 2.61–2.50 (m, 1H), 
2.38 (s, 3H), 2.37–2.27 (m, 3H), 2.18 (s, 3H), 2.13–1.55 (m, 
10H), 1.54–1.26 (m, 3H), 1.19 (d, J = 6.8 Hz, 3H), 1.06 (d, J 
= 6.4 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H), 0.78 (t, J = 7.4 Hz, 
3H), 0.72 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CD
3
OD) d: 
175.9, 173.5, 171.8, 171.3, 162.7, 151.0, 139.6, 130.6, 130.1, 
129.4, 129.3, 129.1, 127.5, 71.4, 69.8, 59.7, 56.5, 55.5, 51.1, 
44.5, 42.0, 39.6, 38.0, 36.4, 32.0, 31.3, 25.6, 25.4, 23.8, 21.1, 
21.0, 20.8, 18.9, 16.4, 11.0. Mass spectrometry (MS) electro-
spray ionisation (ESI) m/z: 804.4 [M+H]+, 826.4 [M+Na]+.
KEMTUB010: (2S,4R)-4-(2-((1R,3R)-1-acetoxy-
3-((2S,3S)-N-benzyl-3-methyl-2-((R)-1-methylpiper-
idine-2-carboxamido)pentanamido)-4-methylpentyl)
thiazole-4-carboxamido)-5-(4-fluorophenyl)-2-methylpen-
tanoic acid
R
f
 = 0.25 (dichloromethane/methanol 95:5). 1H NMR 
(400 MHz, CD
3
OD) d: 8.06 (s, 1H), 7.47 (d, J = 7.1 Hz, 
2H), 7.39–7.08 (m, 5H), 6.90 (t, J = 8.8 Hz, 2H), 5.88 (t, J = 
6.6 Hz, 1H), 5.05 (d, J = 16.6 Hz, 1H), 4.72 (d, J = 9.0 Hz, 
1H), 4.46 (d, J = 16.9 Hz, 2H), 4.42–4.24 (m, 2H), 3.23–3.05 
(m, 2H), 2.95–2.83 (m, 2H), 2.62–2.51 (m, 2H), 2.47 (s, 
3H), 2.38–2.28 (m, 2H), 2.16 (s, 3H), 2.10–1.98 (m, 2H), 
1.95–1.28 (m, 10H), 1.22–1.16 (m, 3H), 1.05 (d, J = 6.4 Hz, 
3H), 0.85 (d, J = 6.6 Hz, 3H), 0.75 (t, J = 7.3 Hz, 3H), 0.69 
(d, J = 6.6 Hz, 3H); 13C NMR (101 MHz, CD
3
OD) d: 181.6, 
176.0, 173.5, 171.8, 171.4, 162.7, 161.9, 151.0, 139.6, 135.6, 
132.3, 132.2, 130.0, 129.3, 129.1, 125.2, 116.1, 115.9, 71.4, 
69.9, 59.7, 56.5, 55.5, 51.1, 44.5, 41.2, 39.5, 39.0, 38.0, 36.5, 
32.0, 31.3, 25.6, 25.4, 23.8, 21.1, 21.0, 20.8, 19.0, 16.4, 10.9; 
19F NMR (376.45 MHz, CD
3
OD) d: -119.0 (s, 1F). MS (ESI) 
m/z: 822.4 [M+H]+, 844.4 [M+Na]+.
KEMTUB012: (2S,4R)-4-(2-((1R,3R)-1-acetoxy-
3-((2S,3S)-N-(cyclopropylmethyl)-3-methyl-2-((R)-1-meth-
ylpiperidine-2-carboxamido)pentanamido)-4-methylpentyl)
thiazole-4-carboxamido)-2-methyl-5-phenylpentanoic acid
R
f
 = 0.27 (dichloromethane/methanol 90:10). 1H NMR 
(400 MHz, CD
3
OD) d: 8.09 (s, 1H), 7.44–6.98 (m, 5H), 
5.90 (d, J = 13.2 Hz, 1H), 4.87–4.79 (m, 1H), 4.44–4.28 
(m, 1H), 3.84 (dd, J = 16.5, 5.5 Hz, 1H), 3.15–3.03 (m, 1H), 
3.02–2.85 (m, 4H), 2.63–2.38 (m, 3H), 2.35 (s, 3H), 2.17 (s, 
3H), 2.08–1.84 (m, 4H), 1.83–1.50 (m, 6H), 1.49–1.20 (m, 
4H), 1.16 (d, J = 7.0 Hz, 3H), 1.14–1.08 (m, 1H), 1.05 (d, J 
= 6.4 Hz, 3H), 1.00 (d, J = 6.8 Hz, 3H), 0.94 (t, J = 7.2 Hz, 
3H), 0.88–0.78 (m, 3H), 0.77–0.55 (m, 2H), 0.54–0.39 (m, 
1H), 0.38–0.25 (m, 1H); 13C NMR (101 MHz, CD
3
OD) d: 
181.4, 173.0, 172.1, 171.8, 162.9, 151.0, 139.7, 130.7, 129.5, 
127.5, 125.2, 71.6, 69.7, 56.5, 55.6, 51.1, 44.3, 42.2, 39.4, 
39.8, 38.7, 38.1, 36.7, 31.9, 31.2, 25.6, 25.5, 23.6, 21.1, 21.0, 
20.7, 18.8, 16.7, 13.2, 11.2, 6.6, 6.4. MS (ESI) m/z: 768.4 
[M+H]+, 790.4 [M+Na]+.
The tubulysin-based conjugates KEMTUB001-NI1, 
KEMTUB012-NI1, KEMTUB012-NI2, and KEMTUB012-
NI3 were synthesized according to the following procedures.
KEMTUB001-NI1: (1R,3R)-3-((2S,3R)-N-benzyl-
3-methyl-2-((R)-1-methylpiperidine-2-carboxamido)
pentanamido)-4-methyl-1-(4-(((2R,4S)-4-methyl-5-((2-(2-
nitro-1H-imidazol-1-yl)ethyl)amino)-5-oxo-1-phenylpentan-
2-yl)carbamoyl)thiazol-2-yl)pentyl acetate
To a solution of KEMTUB001 (0.037 mmol) in dichlo-
romethane (3 mL), 1-[Bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 
(HATU) (0.041 mmol), 1-hydroxy-7-azabenzotriazole 
(HOAt) (0.041 mmol), 2-(2-nitro-1H-imidazol-1-yl)ethana-
mine (0.056 mmol), and triethylamine (0.078 mmol) were 
added. The reaction mixture was stirred for 4 h and then 
washed with water (5 mL). The organic phase was extracted 
with dichloromethane (3×5 mL), and the combined organic 
extracts were dried over Na
2
SO
4
 and concentrated in vacuo. 
The crude product thus obtained was purified by flash chro-
matography (dichloromethane/methanol, 90:10), affording 
34.3 mg of KEMTUB001-NI1 as a yellow foam (yield: 98%).
R
f
: 0.31 (dichloromethane/methanol 90:10). 1H NMR 
(400 MHz, CD
3
OD) d: 8.07 (s, 1H), 7.52–7.43 (m, 3H), 
7.36–7.09 (m, 9H), 7.06 (d, J = 1.2 Hz, 1H), 5.91 (dd, J = 
11.1, J = 2.3 Hz, 1H), 5.09 (d, J = 17.1 Hz, 1H), 4.69 (d, 
J = 9.0 Hz, 1H), 4.62–4.42 (m, 4H), 4.26–4.14 (m, 1H), 
3.69–3.55 (m, 2H), 3.01–2.92 (m, 1H), 2.90–2.75 (m, 2H), 
2.65 (dd, J = 11.1, J = 2.8 Hz, 1H), 2.45–2.32 (m, 2H), 2.24 
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Hypoxia-targeted tubulysin
(s, 3H), 2.17 (s, 3H), 2.15–2.08 (m, 1H), 2.06–1.72 (m, 5H), 
1.71–1.24 (m, 9H), 1.14–0.92 (m, 9H), 0.87 (d, J = 6.6 Hz, 
3H), 0.73 (t, J = 7.5 Hz, 3H), 0.65 (d, J = 6.8 Hz, 3H); 13C 
NMR (101 MHz, CD
3
OD) d: 179.3, 176.4, 175.1, 171.9, 
171.4, 162.9, 150.9, 139.9, 139.3, 130.6, 130.1, 129.5, 129.4, 
129.2, 129.0, 128.6, 127.6, 125.4, 71.3, 70.6, 56.7, 55.4, 51.0, 
50.6, 45.0, 42.6, 40.1, 39.9, 39.0, 38.0, 36.5, 32.0, 31.8, 26.2, 
25.4, 24.4, 21.1, 20.9, 20.7, 19.5, 16.5, 10.9; MS (ESI) m/z: 
942.5 (M++H+), 964.4 (M++Na).
K E M T U B 0 1 2 - N I 1 :  ( 1 R , 3 R ) - 3 - ( ( 2 S , 3 R ) -
N - ( c y c l o p r o p y l m e t h y l ) - 3 - m e t h y l - 2 - ( ( R ) -
1 - m e t h y l p i p e r i d i n e - 2 - c a r b o x a m i d o )
pentanamido)-4-methyl-1-(4-(((2R,4S)-4-methyl-5-((2-(2-
nitro-1H-imidazol-1-yl)ethyl)amino)-5-oxo-1-phenylpentan-
2-yl)carbamoyl)thiazol-2-yl)pentyl acetate
To a solution of KEMTUB012 (0.065 mmol) in dichloro-
methane (4 mL), HATU (0.071 mmol), HOAt (0.071 mmol), 
2-(2-nitro-1H-imidazol-1-yl)ethanamine (0.097 mmol), and 
triethylamine (0.14 mmol) were added. The reaction mixture 
was stirred for 4 h and then washed with water (10 mL). 
The organic phase was extracted with dichloromethane 
(3×10 mL) and the combined organic extracts were dried over 
Na
2
SO
4
 and concentrated in vacuo. The crude product thus 
obtained was purified by flash chromatography (chloroform/
methanol 95:5), affording 58.5 mg of KEMTUB012-NI1 as 
a white foam (yield: 99%).
R
f
: 0.37 (dichloromethane/methanol 90:10). 1H NMR 
(400 MHz, CD
3
OD) d: 8.11 (s, 1H), 7.49–7.43 (m, 1H), 
7.30–7.12 (m, 5H), 7.07 (d, J = 1.2 Hz, 1H), 5.92 (dd, J = 
11.2, J = 2.4 Hz, 1H), 4.91–4.83 (m, 1H), 4.62–4.46 (m, 
2H), 4.29–4.16 (m, 1H), 3.90 (dd, J = 15.8, J = 5.3 Hz, 1H), 
3.70–3.54 (m, 2H), 3.04–2.83 (m, 4H), 2.60 (dd, J = 11.0, J 
= 2.9 Hz, 1H), 2.50–2.25 (m, 3H), 2.19 (s, 3H), 2.17 (s, 3H), 
2.14–2.04 (td, J = 11.7, J = 3.1 Hz, 1H), 2.03–1.84 (m, 3H), 
1.83–1.71 (m, 2H), 1.71–1.45 (m, 5H), 1.38–1.15 (m, 3H), 
1.15–0.98 (m, 10H), 0.97–0.86 (m, 3H), 0.80 (d, J = 6.6, 3H), 
0.76–0.57 (m, 2H), 0.55–0.41 (dd, J = 9.7, J = 4.5 Hz, 1H), 
0.40–0.26 (m, 1H); 13C NMR (101 MHz, CD
3
OD) d: 177.9, 
174.4, 173.9, 170.6, 170.5, 161.6, 149.5, 138.1, 129.3, 128.1, 
128.0, 127.2, 126.2, 124.1, 70.0, 69.2, 55.3, 53.8, 49.6, 49.2, 
43.6, 41.2, 38.7, 38.4, 37.6, 36.8, 35.4, 30.4, 30.4, 24.9, 24.3, 
23.0, 19.7, 19.6, 19.2, 18.1, 15.4, 12.1, 9.8, 5.5, 5.2; MS (ESI) 
m/z: 906.5 (M++H+), 928.5 (M++Na).
K E M T U B 0 1 2 - N I 2 :  ( 1 R , 3 R ) - 3 - ( ( 2 S , 3 R ) -
N - ( c y c l o p r o p y l m e t h y l ) - 3 - m e t h y l - 2 - ( ( R ) -
1 - m e t h y l p i p e r i d i n e - 2 - c a r b o x a m i d o )
pentanamido)-4-methyl-1-(4-(((2R,4S)-4-methyl-5-((3-(2-
(2-nitro-1H-imidazol-1-yl)acetamido)propyl)amino)-5-oxo-
1-phenylpentan-2-yl)carbamoyl)thiazol-2-yl)pentyl acetate
To a solution of KEMTUB012 (0.052 mmol) in N,N-
dimethyl formamide (DMF) (3 mL), HATU (0.057 mmol), 
HOAt (0.057 mmol), N-(3-aminopropyl)-2-(2-nitro-1H-
imidazol-1-yl)acetamide (0.062 mmol), and triethylamine 
(0.11 mmol) were added. The reaction mixture was stirred 
for 4 h and then washed with water (10 mL). The organic 
phase was extracted with dichloromethane (3×10 mL), and 
the combined organic extracts were dried over Na
2
SO
4
 and 
concentrated in vacuo. The crude product thus obtained was 
purified by flash chromatography (chloroform/methanol 
95:5), affording 42.4 mg of KEMTUB012-NI2 as a white 
foam (yield: 83%).
R
f
: 0.22 (dichloromethane/methanol 90:10). 1H NMR 
(400 MHz, CD
3
OD) d: 8.09 (s, 1H), 7.46 (d, J = 1.2 Hz, 1H), 
7.29–7.19 (m, 4H), 7.18–7.13 (m, 2H), 5.93 (dd, J = 11.2, J = 
2.2 Hz, 1H), 5.17 (s, 2H), 4.91–4.83 (m, 1H), 4.34–4.22 (m, 
1H), 3.90 (dd, J = 15.9, J = 5.4 Hz, 1H), 3.31–3.20 (m, 2H), 
3.19–3.06 (m, 1H), 3.02–2.80 (m, 4H), 2.58 (dd, J = 11.1, J = 
2.80 Hz, 1H), 2.53–2.27 (m, 3H), 2.18 (s, 3H), 2.17 (s, 3H), 
2.14–1.84 (m, 4H), 1.83–1.47 (m, 9H), 1.43–1.17 (m, 3H), 
1.15–1.05 (m, 7H), 1.04–0.99 (m, 3H), 0.98–0.91 (m, 3H), 
0.81(d, J = 6.6, 3H), 0.77–0.59 (m, 2H), 0.55–0.44 (m, 1H), 
0.40–0.27 (m, 1H); 13C NMR (101 MHz, CD
3
OD) d: 178.8, 
175.8, 175.4, 172.0, 171.7, 171.5, 168.2, 163.0, 150.9, 139.5, 
130.7, 129.5, 128.5, 127.6, 125.5, 71.4, 70.7, 56.7, 55.2, 53.0, 
50.7, 45.0, 42.7, 40.0, 39.1, 38.3, 38.2, 37.7, 36.7, 31.8, 31.8, 
30.1, 26.3, 25.7, 24.4, 21.1, 21.0, 20.6, 19.4, 16.8, 13.5, 11.2, 
6.9, 6.6; MS (ESI) m/z: 977.3 (M++H+), 1,000.3 (M++Na).
K E M T U B 0 1 2 - N I 3 :  ( 1 R , 3 R ) - 3 - ( ( 2 S , 3 R ) -
N - ( c y c l o p r o p y l m e t h y l ) - 3 - m e t h y l - 2 - ( ( R ) -
1 - m e t h y l p i p e r i d i n e - 2 - c a r b o x a m i d o )
pentanamido)-4-methyl-1-(4-(((2R,4S)-4-methyl-5-((6-(2-
(2-nitro-1H-imidazol-1-yl)acetamido)hexyl)amino)-5-oxo-
1-phenylpentan-2-yl)carbamoyl)thiazol-2-yl)pentyl acetate
To a solution of KEMTUB012 (0.065 mmol) in DMF 
(3 mL), HATU (0.071 mmol), HOAt (0.071 mmol), N-(6-
aminohexyl)-2-(2-nitro-1H-imidazol-1-yl)acetamide 
(0.08 mmol), and triethylamine (0.14 mmol) were added. 
The reaction mixture was stirred for 4 h and then washed 
with water (10 mL). The organic phase was extracted with 
dichloromethane (3×10 mL), and the combined organic 
extracts were dried over Na
2
SO
4
 and concentrated in vacuo. 
The crude product thus obtained was purified by flash chro-
matography (chloroform/methanol 95:5), affording 66.0 mg 
of KEMTUB012-NI3 as a yellow oil (yield: quantitative).
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B
Figure S1 Scheme demonstrating synthesizes of tubulysin analogs. (A) Synthesis of NI1 tubulysins. (B) Synthesis of NI2 and NI3 tubulysins.
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R
f
: 0.23 (dichloromethane/methanol 90:10). 1H NMR 
(400 MHz, CD
3
OD) d: 8.11 (s, 1H), 7.44 (d, J = 1.2 Hz, 1H), 
7.28–7.19 (m, 4H), 7.18–7.12 (m, 2H), 5.93 (dd, J = 11.2, J 
= 2.2 Hz, 1H), 5.12 (s, 2H), 4.93–4.83 (m, 1H), 4.33–4.23 
(m, 1H), 3.89 (dd, J = 15.7, J = 5.4 Hz, 1H), 3.29–3.17 (m, 
3H), 3.16–3.07 (m, 2H), 3.03–2.92 (m, 2H), 2.91–2.85 (m, 
2H), 2.67 (dd, J = 11.0, J = 2.69 Hz, 1H), 2.53–2.28 (m, 3H), 
2.22 (s, 3H), 2.17 (s, 3H), 2.15–2.09 (m, 1H), 2.07–1.94 (m, 
2H), 1.85–1.71 (m, 2H), 1.71–1.45 (m, 9H), 1.44–1.25 (m, 
9H), 1.15–1.05 (m, 7H), 1.04–0.99 (m, 3H), 0.98–0.89 (m, 
3H), 0.81 (d, J = 6.6, 3H), 0.77–0.60 (m, 2H), 0.54–0.42 (m, 
1H), 0.42–0.27 (m, 1H); 13C NMR (101 MHz, CD
3
OD) d: 
178.5, 174.9, 172.0, 171.8, 167.9, 163.0, 150.9, 139.5, 130.6, 
129.5, 129.5, 128.5, 127.6, 125.5, 71.4, 70.5, 56.7, 55.2, 53.0, 
50.9, 44.8, 42.5, 40.6, 40.3, 40.1, 39.1, 38.2, 36.8, 33.2, 31.8, 
31.7, 30.4, 30.3, 27.6, 27.5, 26.1, 25.7, 24.3, 21.1, 21.0, 20.6, 
19.4, 18.5, 16.7, 13.5, 11.2, 6.9, 6.6; MS (ESI) m/z: 1,019.5 
(M++H+), 1,042.4 (M++Na).
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